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In Brief
While antibodies generally neutralize
viruses by bivalent binding to neighboring
virion spikes, HIV-1 virion and spike
architectures generally prohibit both
inter- and intra-spike crosslinking by
naturally occurring antibodies. Newly
engineered antibody-based molecules,
rationally designed for high-avidity
intraspike binding, overcome this barrier
and exhibit >100-fold increases in HIV-1
neutralization potencies.
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Antibodies developed during HIV-1 infection lose
efficacy as the viral spike mutates. We postulated
that anti-HIV-1 antibodies primarily bind monova-
lently because HIV’s low spike density impedes
bivalent binding through inter-spike crosslinking,
and the spike structure prohibits bivalent binding
through intra-spike crosslinking. Monovalent binding
reduces avidity and potency, thus expanding the
range of mutations permitting antibody evasion. To
test this idea, we engineered antibody-based mole-
cules capable of bivalent binding through intra-spike
crosslinking. We used DNA as a ‘‘molecular ruler’’
to measure intra-epitope distances on virion-bound
spikes and construct intra-spike crosslinking mole-
cules. Optimal bivalent reagents exhibited up to 2.5
orders of magnitude increased potency (>100-fold
average increases across virus panels) and identified
conformational states of virion-bound spikes. The
demonstration that intra-spike crosslinking lowers
the concentration of antibodies required for neutrali-
zation supports the hypothesis that low spike den-
sities facilitate antibody evasion and the use of mol-
ecules capable of intra-spike crosslinking for therapy
or passive protection.INTRODUCTION
The HIV-1 envelope (Env) spike trimer, a trimer of gp120 and
gp41 subunits, is the only target of neutralizing antibodies.
The spike utilizes antibody-evasion strategies, including muta-
tion, glycan shielding, and conformational masking (West et al.,
2014). Although important, these features are not unique to
HIV-1; other viruses employing these strategies elicit IgG anti-
body responses that provide sterilizing immunity or viral clear-
ance. A potentially unique antibody-evasion strategy for HIV-1
involves hindering IgGs from using both antigen-binding frag-
ments (Fabs) to bind bivalently to spikes (Klein and Bjorkman,2010; Mouquet et al., 2010). This is accomplished by the small
number and low density of Env spikes (Chertova et al., 2002;
Liu et al., 2008; Zhu et al., 2006), which prevent most IgGs
from inter-spike crosslinking (bivalent binding between spikes),
and the architecture of the Env trimer, which impedes intra-spike
crosslinking (bivalent binding within a spike trimer) (Klein et al.,
2009; Luftig et al., 2006).
On a typical virus with closely spaced envelope spikes, an IgG
antibody can bind using both Fabs to crosslink neighboring
spikes, leading to a nearly irreversible antibody-antigen interac-
tion (Mattes, 2005). Avidity effects from bivalent binding of IgG
antibodies have been shown to be critical for neutralization of
many viruses, including polio and influenza (Icenogle et al.,
1983; Schofield et al., 1997). By contrast, the small number of
spikes (14) present on the surface of HIV-1 (Chertova et al.,
2002; Liu et al., 2008; Zhu et al., 2006) impedes simultaneous
engagement of both antibody combining sites (Klein and Bjork-
man, 2010; Mouquet et al., 2010)—most spikes are separated
by distances that far exceed the 15 nm reach of the two Fab
arms of an IgG (Liu et al., 2008; Zhu et al., 2006) (Figure 1A). In-
ter-spike crosslinking might still be possible if spikes could freely
diffuse within the viral membrane. However, cryo-electron to-
mography of HIV-1 (Zhu et al., 2006) and evidence for interac-
tions between the cytoplasmic tail of gp41 and thematrix protein
of HIV (Bhatia et al., 2009; Crooks et al., 2008; Yu et al., 1992)
suggest that a virion’s spike distribution is likely to be relatively
static over timescales relevant to neutralization. Taken together,
the mechanisms to hinder inter- and intra-spike crosslinking
imply that most anti-HIV-1 IgGs bind monovalently to virions.
It seems an unlikely coincidence that HIV-1, among the most
adept of viruses at evading antibody-mediated neutralization,
has an unusually low density of surface envelope spikes with
restricted mobility, as well as an unusually high mutation rate.
We speculated that HIV-1 evolved a low spike density to hinder
bivalent binding by antibodies (Klein and Bjorkman, 2010) and
postulated that the combination of predominantly monovalent
IgG binding andHIV-1’s rapidmutation rate creates an additional
effective antibody evasion strategy (Klein and Bjorkman, 2010). If
the affinity between an IgG Fab and a viral spike is high enough,
monovalent IgG binding to a virion should not, in and of itself,
hinder or prevent viral neutralization. Thus, affinity-matured
anti-Env IgGs raised against a particular strain of virus canCell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc. 433
Figure 1. IgG and diFab Reagents Binding
to Viral Spikes
(A) Top: IgG binding monovalently to spikes on
HIV-1 surfaces, which include a small number
(14) and low density of Env (Chertova et al., 2002;
Liu et al., 2008; Zhu et al., 2006). Bottom: homo-
diFab reagent binding bivalently to HIV-1 Env by
intra-spike crosslinking. Schematic representa-
tions of Env adapted from figures in Liu et al.
(2008).
(B) Schematic of method used to produce homo-
and hetero-diFabs.
See also Figure S1.effectively neutralize autologous virus (Klein et al., 2013; West
et al., 2014). However, upon mutation of an antibody epitope
on Env, the low affinity of themonovalent Fab-antigen interaction
would result in either complete loss of neutralization or neutrali-
zation only at very high concentrations. These concepts are illus-
trated by comparisons of binding and neutralization for variants
of IgG and Fab forms of palivizumab, a neutralizing IgG against
respiratory syncytial virus (RSV) (Wu et al., 2005), a virus with434 Cell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc.a high density of Env spikes (Liljeroos
et al., 2013). Palivizumab Fabs with fast
off-rates/low affinities exhibited 2–3 log
improvements in neutralization potencies
when converted to bivalent IgGs, and the
potencies of the IgGs were not affected
by mutations that increased the off-rates
of their corresponding monovalent Fabs
by >100-fold (Wu et al., 2005), illustrating
the importance of avidity for IgGs with
weak ormoderate affinity Fabs. However,
high affinity/slow off-rate palivizumab
Fabs were equally as potent as their IgG
counterparts, which could bind bivalently
to RSV through inter-spike crosslinking.
In the palivizumab example, binding and
neutralization potencies were evaluated
for a single strain of virus and antibodies.
In the case of HIV-1, we are interested in
the effects of mutations in the virus on
binding of the same antibody, but the
effects of mutation are expected to be
similar. Thus, we postulate that avidity ef-
fects through bivalent binding can serve
as a buffer to dampen the effects of viral
mutations on neutralization potencies of
IgGs.
This line of reasoning suggests that
bivalent HIV-1 binders would be optimal
for passive prevention or immuno-
therapy, but because inter-spike dis-
tances are not constant, even on a single
virion, it is not possible to engineer re-
agents that could consistently accom-
plish inter-spike crosslinking. In contrast,
reagents that can bind bivalently to a sin-gle trimeric spike would function independently of both spike
density and distribution (Pace et al., 2013). To test the idea
that intra-spike crosslinking results in increased neutralization
potency, we used molecular rulers to map epitopes on virion-
bound HIV-1 spikes and created molecules designed to syner-
gize through bivalent interactions within single Env trimers
(Figure 1A). We developed methods to produce multiple combi-
nations of Env binders separated by different distances by
attaching broadly neutralizing antibody (bNAb) Fabs to variable-
length double-stranded DNA (dsDNA) (Figures 1B and S1). We
chose dsDNA as a linker because its long persistence length
(460–500 A˚ [Bednar et al., 1995] compared with 30 A˚ for pep-
tides [Zhou, 2004]) permits its use as a molecular ruler with
3.4 A˚/base pair (bp) increments. Here, we show that homo-
and hetero-diFabs joined by optimal-length dsDNA bridges
can achieve neutralization potency increases of two to three or-
ders of magnitude and provide evidence that the synergy results
from intra-spike crosslinking. Upon determining the optimal
distances between Env trimer-bound Fabs, we show that it is
possible to convert the dsDNA bridge to a protein linker to create
a protein-based reagent with similar synergistic properties.
These results illustrate the importance of avidity in antibody-
pathogen interactions, elucidate mechanisms by which HIV-1
evades the host immune system, and are relevant to the choice
of potential protein therapeutics to be delivered to prevent or
treat HIV-1 infections.
RESULTS
Homo-diFabs Exhibit Length-Dependent Avidity Effects
Consistent with Intra-Spike Crosslinking
Fabsweremodified to contain a free thiol and then conjugated to
maleimide-activated single-stranded DNA (ssDNA) (Figure 1B).
Different lengths of dsDNA (designed to lack secondary struc-
tures [Zadeh et al., 2011]) (Extended Experimental Procedures
and Table S6) were annealed with and ligated to the ssDNA-
Fab conjugates to create homo- or hetero-diFabs, in which the
two Fabs were the same or different, respectively. Dynamic light
scattering confirmed that conjugates with longer DNA bridges
were more extended (Figure 2A), supporting the use of dsDNA
as a ruler. Inter-Fab distances calculated from dsDNA lengths
were regarded as approximate because the DNA linkers
included short regions of ssDNA (persistence length 22 A˚) (Chi
et al., 2013) to permit orientational flexibility.
We first determined the optimal dsDNA linker for a homo-di-
Fab constructed from 3BNC60, a bNAb against the CD4 binding
site (CD4bs) on the gp120 subunit of Env (Scheid et al., 2011), by
evaluating homo-diFabs with different dsDNA lengths using
in vitro neutralization assays. The 50% inhibitory concentrations
(IC50s) against HIV-1 strain 6535.3 depended on the dsDNA
length, with the most potent homo-diFab containing a bridge
of 62 bp (211 A˚) (Figures 2B and S2). This length is close to
the predicted distance (198 A˚) between the C termini of
adjacent 3BNC60 Fabs bound to the open structure of an HIV-
1 trimer (Merk and Subramaniam, 2013) (Figures 3 and S3).
Bridge lengths of 60 bp also exhibited the best potencies for
3BNC60 homo-diFabs against DU172.17 HIV-1 and for homo-
diFabs constructed from VRC01 (Wu et al., 2010), a related
CD4bs bNAb (Figure S2). The 100-fold increased potency of
3BNC60-62bp-3BNC60 compared with 3BNC60 IgG against
HIV-1 6535.3 (Figure 2B) suggested synergy resulting from avid-
ity effects due to bivalent binding. The bivalent interaction likely
resulted from intra-spike crosslinking rather than inter-spike
crosslinking because the latter should not manifest with a sharp
length dependence because inter-spike distances are variable
within and between virions (Liu et al., 2008; Zhu et al., 2006).To formally assess the extent to which inter-spike crosslinking
could contribute to synergy, we evaluated homo-diFabs con-
structed from the V1V2 loop-specific bNAb PG16 (Walker
et al., 2009), which cannot crosslink within a single spike
because only one anti-V1V2 Fab binds per Env trimer (Julien
et al., 2013b). PG16 homo-diFabs with different dsDNA bridges
did not exhibit length-dependent neutralization profiles against
strain 6535.3 (Figure 2B) and other viral strains (Figure S2D).
However, increased potencies were observed for PG16 homo-
diFabs withR70 bp or 80 bp (R248 A˚ or 272 A˚) bridges, perhaps
reflecting increased inter-spike crosslinking with longer separa-
tion distances (Figures 2B and S2D).
Comparison of Homo-diFabs that Can or Cannot Exhibit
Intra-Spike Crosslinking
To evaluate the potential for intra-spike crosslinking across
different viral strains, we compared homo-diFabs designed to
be capable (b12 and 3BNC60) or incapable (PG16) of intra-spike
crosslinking (Figure 2C). Tominimize inter-spike crosslinking, the
homo-diFabs were constructed with 60–62 bp bridges. The b12-
60bp-b12 homo-diFab exhibited increased potency compared
with b12 IgG in 21 of 25 strains in a cross-clade panel of primary
HIV-1, with potency increases R10-fold for 16 strains and a
geometric mean potency increase of 22-fold. 3BNC60-62bp-
3BNC60 showed even more consistent synergy, being more
potent than 3BNC60 IgG against all 25 strains tested, with
R10-fold increases for 20 strains and a mean increase of 19-
fold. By contrast, the PG16-60bp-PG16 homo-diFab showed
potency increases compared with PG16 IgG against only six
strains, with relatively small (2- to 7-fold) increases in five strains
and an overall 2.8-fold mean potency change.
Hetero-diFabs Exhibit Dramatic Potency Increases
Consistent with Intra-Spike Crosslinking
To determine whether heterotypic bivalent binding can produce
synergy and to measure distances between epitopes, we used
dsDNA to link Fabs recognizing different epitopes on gp120.
We first evaluated hetero-diFabs constructed with Fabs from
V1V2 (PG16 or PG9) (Walker et al., 2009) and CD4bs (b12 or
3BNC60) (Roben et al., 1994; Scheid et al., 2011) bNAbs linked
with 60 bp dsDNA bridges. PG16-60bp-b12 hetero-diFabs
were evaluated in neutralization assays against HIV-1 strains
SC4226618 (more sensitive to b12 than PG16) and CAP210
(more sensitive to PG16 than b12). According to the model being
tested, in the absence of synergistic binding; i.e., when only one
Fab can bind to a spike at a time, a hetero-diFab would be no
more potent than a non-covalent mixture of the dsDNA and the
two Fabs against each viral strain, whereas synergistic binding
would result in avidity effects exhibited by increased potency
of the hetero-diFab. For both viral strains, the PG16-60bp-b12
hetero-diFab was 10-fold more potent than the mixture of
Fabs plus dsDNA or the more potent of the two Fabs alone (Fig-
ures 4 and S4). To more systematically explore potential syn-
ergy, we evaluated PG16-60bp-b12 against a 25 member panel
of HIV-1 strains, finding synergistic effects (between 2- and 145-
fold more potent than the corresponding non-covalent mixture
for most strains; geometric mean improvement of 4.7-fold)
(Table S1). When Fabs from PG16 or PG9 were combined withCell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc. 435
Figure 2. Characterization of Homo-diFabs
(A) Dynamic light-scattering measurements of hydrodynamic radii for IgG and Fab proteins, different lengths of dsDNA alone, and di-Fabs with different dsDNA
linkers.
(B) Effects of dsDNA bridge length on neutralization potencies of 3BNC60 and PG16 homo-diFabs against the Tier 1BHIV-1 strain 6535.3. Neutralization IC50s are
plotted against the length of the dsDNA linker. IC50s for the parent IgG and Fab are indicated as red and blue lines, respectively.
(legend continued on next page)
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Figure 3. Comparison of Intra-Spike Dis-
tances for Three Conformations Found for
Virion-Associated HIV-1 Env Spike Trimers
(A) Three conformations of Env trimers shown
as surface representations (top row: gp120 co-
ordinates only) and schematically (bottom two
rows). Schematic representations of Env trimers
adapted from figures in Liu et al. (2008). Env spikes
are shown as seen from above (top and middle
rows) and the side (bottom row). V1V2 loops are
cyan, V3 loops are purple, the CD4 binding site is
yellow, the remainder of gp120 is maroon, gp41 is
green, and the membrane bilayer is gray. The
closed structure (PDB code 4NCO) was observed
for unliganded trimers (Liu et al., 2008) and trimers
associated with Fabs from potent VRC01-like
(PVL) antibodies (Lyumkis et al., 2013; Merk and
Subramaniam, 2013). The open structure was
observed for trimers associated with CD4 or the
Fab from the CD4-induced antibody 17b (Merk
and Subramaniam, 2013; Tran et al., 2012) (co-
ordinates obtained from S. Subramaniam). The
partially open structure was observed for trimers
associated with the Fab from b12 (Liu et al., 2008;
Merk and Subramaniam, 2013) (PDB code 3DNL).
(B) Measured distances between homo-diFabs
bound to HIV-1 trimer structures. Fabs from the
indicated bNAbs are shown bound to the gp120
portions of Env in the three conformation shown in
(A). Fabs are shown as ribbons; gp120 subunits
are shown as surface representations with V1V2
loops in cyan, V3 in purple, the CD4 binding site in
yellow, and the remainder of gp120 inmaroon. The
distance between the Cys233heavy chain carbon-a
atoms of adjacent bound Fabs is indicated by a
gray line as an approximation of an optimal length
for a dsDNA bridge attached to Cys233heavy chain.
Assuming 3-fold symmetry of trimers, only one
distance is possible for bound 3BNC60, b12, and
10-1074 homo-diFabs.
See also Figure S3.a more potent CD4bs-recognizing bNAb (3BNC60), the result-
ing hetero-diFabs exhibited greater synergy—several examples
of >150-fold improvement for PG16-60bp-3BNC60 and PG9-
60bp-3BNC60 and geometric mean potency improvements of
29- and 68-fold, respectively (Figure 4 and Tables S2 and S3).
Other hetero-diFabs, constructed with combinations of Fabs
recognizing the CD4bs (3BNC60 [Scheid et al., 2011]), the(C) Neutralization of primary HIV-1 strains by b12 and PG16 homo-diFabs, each constructed with a 60 bp dsD
the parental Fabs and IgGs, and dsDNA alone. As a measure of potential synergy, the molar ratio of the IC50
each strain in parentheses beside the IC50 for the homo-diFab.
See also Figure S2.
Cell 160, 433–446gp120 V3 loop (10-1074 [Mouquet et al.,
2012]), and a gp41 epitope (10E8 [Huang
et al., 2012]), also showed synergistic
effects (Figure 4 and Table S4), and
a 3BNC60-60bp-b12 hetero-diFab ex-
hibited up to 660-fold synergy and a geo-
metric mean potency increase of 90-fold(Figure 4 and Table S5). In contrast, analogous IgG hetero-
dimers, constructed with two different Fabs linked to a single
Fc (Schaefer et al., 2011), did not show synergy when evaluated
against the same viruses, demonstrating that synergistic effects
required optimal separation distances that permitted each Fab
to achieve its specific binding orientation (Figure S4 and Tables
S1, S2, S3, S4, and S5). We conclude that hetero-diFabs canNA bridge. IC50s are reported for the homo-diFabs,
values for the IgG and the homo-diFab is listed for
, January 29, 2015 ª2015 Elsevier Inc. 437
Figure 4. Synergistic dsDNA-Based Hetero-diFabs
Neutralization of primary HIV-1 strains by hetero-diFabs. IC50s are reported for the hetero-diFabs. See Tables S1, S2, S3, S4, and S5 for IC50s of parental Fabs
and IgGs, dsDNA alone, and the non-covalent mixtures of Fabs and dsDNA. As a measure of potential synergy of each hetero-diFab, the molar ratio of the IC50
values for the non-covalent mixture and the hetero-diFab is listed for each strain in parentheses beside the IC50 for the hetero-diFab. NT, not tested. See also
Figure S4.
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Figure 5. Synergistic Protein-Based Het-
ero-diFab
(A) Schematic representation of PG16-TPR12-
3BNC60 (not to scale). Approximate lengths are
indicated (120 A˚ for the TRP12 linker plus 11 A˚
for the fused click handles).
(B) Neutralization of primary HIV-1 strains. IC50s
are reported for PG16-TPR12-3BNC60, the
parental components of the reagent (PG16 Fab
and 3BNC60 Fab-TPR12), and TPR12 alone. As a
measure of potential synergy of PG16-TPR12-
3BNC60, the molar ratio of the IC50 values for the
most potent component and PG16-TPR12-
3BNC60 is listed for each strain in parentheses
beside the IC50 for PG16-TPR12-3BNC60.
See also Figure S5.achieve synergy through simultaneous recognition of two
different epitopes on the same HIV-1 Env trimer.
To more precisely define optimal intra-epitope separation
distances, we evaluated hetero-diFabs with different bridge
lengths, finding length-dependent synergy effects. For example,
PG16-3BNC60 hetero-diFabs with 40 bp and 50 bp dsDNA
bridges showed improved neutralization potencies when
compared to the 60 bp (204 A˚) version, achievingR100-fold po-
tency increases against over half of the tested strains and geo-
metric mean improvements of 98- and 107-fold, respectively
(Figure 4 and Table S4). The 40 bp and 50 bp bridges (136 A˚
and 170 A˚, respectively) corresponded to the approximate sep-
aration distances between PG16 and 3BNC60 Fabs when bound
to the same gp120 within a trimer (147 A˚) or to neighboring
protomers within open or partially open trimers (167 A˚) (Fig-
ure S3). In a second length dependency example, 10-1074-
40bp-3BNC60 was more potent than 10-1074-60bp-3BNC60Cell 160, 433–446(Figure 4 and Table S4). The 136 A˚
distance between the two Fabs in 10-
1074-40bp-3BNC60 corresponded to
the approximate separation between
these Fabs bound to the same gp120
(141 A˚), whereas 60 bp more closely
approximated Fabs bound to neigh-
boring protomers on an open trimer
(193 A˚) (Figure S3). The 40 bp and 50 bp
versions of 10E8-3BNC60 showed
consistent synergy (Figure 4 and Table
S4); however, the lack of structural infor-
mation concerning 10E8 binding to Env
trimer hindered interpretation of 10E8-
containing hetero-diFabs.
A Hetero-diFab Constructed with a
Protein Linker Exhibits Synergistic
Potency Increases
Bivalent molecules involving dsDNA
linkers were effective for demonstrating
synergistic neutralization, but a protein
reagent would be preferable as an anti-
HIV-1 therapeutic. We recently describeda series of protein linkers of various lengths and rigidities (Klein
et al., 2014) that can mimic the properties of different lengths
of dsDNA. Thus, we can substitute a comparable protein linker
for an optimal dsDNA bridge to create a protein reagent capable
of simultaneous binding to two different epitopes on a single HIV-
1 spike trimer. As a proof-of-principle example, we used sortase-
catalyzed protein ligation and click chemistry (Witte et al., 2013)
to construct a bivalent reagent analogous to PG16-40bp-
3BNC60 by substituting the dsDNA linker with 12 domains of a
designed tetratricopeptide-repeat (TPR) protein (Kajander
et al., 2007) (Figures 5A and S5). We chose a TPR linker because
tandem repeats of TPR domains form a rigid rod-like structure
whose length corresponds predictably with the number of re-
peats, with each domain contributing 10 A˚ (Kajander et al.,
2007). PG16 Fab was expressed with a C-terminal sortase
signal, and the C terminus of the 3BNC60 Fab was modified to
include 12 TPR repeats and a sortase signal. The tagged Fabs, January 29, 2015 ª2015 Elsevier Inc. 439
Figure 6. Simulations of Avidity Effects due to Bivalent Binding of IgG to a Tethered Antigen
(A) The fraction of tethered antigen bound by different concentrations of IgG or Fab after 1 hr shown as a heat map (cooler colors representing a lower percentage
bound and warmer colors representing a higher percentage bound) as a function of kinetic constants for the IgG-antigen or Fab-antigen interaction. The fraction
of antigen bound by a Fab or IgG was calculated as a function of ka and kd. The intrinsic affinities are strongest in the lower right corner (1 pM) and weakest in the
upper left corner (100 mM) of each graph. For IgG, binding was forced to 100% monovalent binding (middle row) or 100% bivalent binding (bottom row).
Saturation by Fabs and IgGs was nearly identical for monovalent binding conditions because the binding kinetics of IgGs would be enhanced by at most 2-fold.
Comparisons of the simulations for bivalent binding (bottom row) and monovalent binding (top two panels) showed regions of saturation binding resulting from
avidity effects.
(B) The fraction of antigen bound as a function of time for IgGs binding to surface-tethered antigens at an input concentration of 10 nM.When the dissociation rate
constant of the Fab portion of the IgG is slow (top) and the input concentration is approximately 100-fold higher than the affinity of the Fab, IgGs can reach
saturation binding after an hour whether binding monovalently or bivalently to the surface—hence, avidity effects are not apparent after an hour. However,
weakening the affinity of the Fab by making the dissociation rate 1,000-fold faster (bottom) prevents saturation when binding monovalently but has no effect on
saturation when binding bivalently—hence, avidity effects are apparent throughout the incubation.were covalently attached to peptides containing click handles
using sortase-catalyzed ligation and then incubated to allow
the click reaction to form PG16 Fab linked to 3BNC60 Fab
by 12 TPR repeats (PG16-TPR12-3BNC60). Together with the
remnants of the click handles, the linker would occupy 131 A˚,
approximately the same length as the dsDNA linker in PG16-
40bp-3BNC60 reagent (Figures 5A and S5). The protein-based
molecule, PG16-TPR12-3BNC60, exhibited between 11- and
>200-fold synergy against 12 primary HIV-1 strains (Figure 5B;
33-fold geometric mean increased potency).
Simulations of the Effects of Avidity on IgG Binding to
Tethered Antigens
To better understand the effects of avidity arising from bivalent
binding of IgGs to antigens tethered to a surface such as a viral
membrane, we used modeling software to simulate the satura-
tion of surface-bound antigens by monovalent Fabs and biva-
lent IgGs. We chose a 1 hr incubation time based upon condi-
tions under which in vitro neutralization assays are conducted
(Montefiori, 2005). We varied the density of the tethered anti-440 Cell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc.gens and the concentrations of Fab or IgG and investigated a
range of intrinsic association and dissociation rate constants
for the binding interaction. The fraction of antigen bound by a
Fab or IgG was calculated as a function of on- and off-rates
(ka and kd), whose ratio (kd/ka) is equal to the affinity (KD, or
equilibrium dissociation constant). We compared saturation
by Fabs (top row), IgGs in which only monovalent binding
was permitted (center row), and IgGs that bound bivalently
through crosslinking of neighboring antigens (bottom row) (Fig-
ure 6A). As expected, saturation by Fabs and IgGs was nearly
identical for monovalent binding conditions (Figure 6A, first two
rows). By contrast, across a range of input concentrations,
there were ka and kd combinations for IgGs binding bivalently
that exhibited saturation binding under conditions in which
monovalent Fabs and IgGs binding monovalently did not (Fig-
ure 6A, bottom row). Thus, consistent with experimental results
in the palivizumab/RSV system (Wu et al., 2005), the simula-
tions suggested that bivalency through crosslinking can rescue
binding of IgGs whose Fabs exhibit weak binding affinities as a
result of fast dissociation rate constants, whereas IgGs whose
Fabs exhibit high affinities because of slow dissociation rates
did not display strong avidity enhancement.
The simulations also demonstrate that the effects of avidity on
binding are a complicated mixture of kinetics, input concentra-
tion, and incubation time. At any particular concentration, the
threshold at which avidity is observed is controlled by kinetics
rather than affinity because different combinations of kinetic
constants yield the same KD. The kinetic threshold at which avid-
ity effects are observed varies depending on the difference be-
tween the input concentration and the KD. For concentrations
near or below the KD, there is a kinetic threshold such that, for
on- and off-rates slower than 103 M1s1 and 105 s1,
respectively, avidity enhancement is not observed (Figure 6A).
The binding reactions are also affected by the length of incuba-
tion, such that the lower the input concentration, the longer it
takes to reach saturation (Figure 6B).
We note that the simulations model binding interactions
only, whereas our homo- and hetero-diFabs were evaluated
for their ability to enhance neutralization of viral infectivity, a
process more complicated than binding. For example, neutral-
ization mechanisms may involve conformational changes in Env
that were not accounted for in our binding simulation. In addi-
tion, kinetics constants for antibody-mediated neutralization of
HIV-1 are not known—nor is the fraction of Env spikes on a
virion that are required for neutralization or for fusion. In any
case, it appears that the kinetic properties of the bNAb Fab
components in our reagents were appropriate to realize avid-
ity-enhanced neutralization because hetero-diFab reagents
displayed 100-fold mean improved neutralization potencies.
The data therefore support the hypothesis that intra-spike
crosslinking by anti-HIV-1 binding molecules represents a valid
strategy for increasing potency and resistance to HIV-1 Env
mutations.
DISCUSSION
We engineered HIV-1 spike-binding molecules designed to bind
bivalently to demonstrate the importance of avidity effects in
antibody efficacy in HIV-1 neutralization and to establish that
lack of bivalent binding by physiologic IgGs is an additional anti-
body evasion strategy utilized by HIV-1.
The importance for HIV-1 in maintaining a low spike density
to avoid inter-spike crosslinking by IgGs was suggested by
the relatively small improvements in neutralization potencies of
intact anti-HIV-1 IgGs compared with their Fab counterparts
(Klein and Bjorkman, 2010) and by the discovery that polyreac-
tivity increased the apparent affinity of anti-HIV-1 antibodies
through a mechanism of heteroligation (Mouquet et al., 2010).
Comparison of the neutralization potencies of IgGs versus
Fabs in the current study provides further support for the obser-
vation that anti-HIV-1 IgGs generally exhibit relatively small
increased potencies compared to Fabs. To quantify potential
avidity effects, we previously defined the molar neutralization ra-
tio (MNR) for IgG versus Fab forms of an antibody as IC50 Fab
(nM)/IC50 IgG (nM). In the absence of avidity or other advantages
of the IgG compared with the Fab (e.g., increased size), the ratio
would be 2.0 (Klein and Bjorkman, 2010). In the current study, the
mean MNR for PG16, an IgG that cannot exhibit intra-spikecrosslinking (Julien et al., 2013b), was 8.0 (data from Figure 2C),
similar to the 10.5 mean MNR in a previous study (West et al.,
2012). These values are lower than MNRs observed for IgGs
against densely packed viruses, which can be over 1,000, but
are consistent with a limited amount of inter-spike crosslinking
by anti-HIV-1 IgGs whose epitopes on neighboring spikes
are accessible to simultaneous engagement of the combining
sites of the two Fabs of an IgG, which are separated by
150 A˚ (Klein and Bjorkman, 2010). Our current results sug-
gested that inter-spike crosslinking can be increased by creating
homo-diFabs with 70 bp–100 bp dsDNA linkers (Figures 2B and
S2D). These linkers would separate the combining sites of the
Fabs byR240–340 A˚, distances that should enhance inter-spike
crosslinking.
Indirect evidence for the hypothesis that HIV-1 evolved a low
spike density to avoid inter-spike crosslinking IgGs comes
from studies of a cytoplasmic tail deletion in the simian immuno-
deficiency virus (SIV) spike trimer. Cytoplasmic tail deletion has
been suggested to increase the number of spikes per virion (Zin-
gler and Littman, 1993) and/or the spike mobility in the virion
bilayer (Crooks et al., 2008), both of which could enhance in-
ter-spike crosslinking. Although tail-deleted mutant viruses can
be produced in vitro, propagation of the virus inmacaques favors
viruses containing the full-length envelope spike (Zingler and
Littman, 1993). These findings are consistent with the idea that
an intact host immune system selects against those viruses
that facilitate the ability of host IgGs to bind bivalently through
inter-spike crosslinking.
Here, we present a method to create potential intra-spike
crosslinking antibody-based molecules using dsDNA- and pro-
tein-based linkers and demonstrate that these reagents can
exhibit up to three orders of magnitude increases in neutraliza-
tion potency. We argue that the optimized versions of our engi-
neered molecules achieve potency increases through intra-
spike, rather than inter-spike, crosslinking because (1) distances
measured between epitopes on virion-bound spike trimers cor-
responded to approximate intra-epitope distances on HIV-1
spike trimer structures, and (2) increases in inter-spike crosslink-
ing by homotypic and heterotypic reagents should not exhibit
sharp linker length-dependent neutralization potencies because
distances between spikes varywithin a single virion and between
virions. The latter point is valid even if HIV-1 spikes are clustered
on mature virions, as suggested by fluorescence nanoscopy
(Chojnacki et al., 2012), but not cryoelectron microscopy (Liu
et al., 2008; Zhu et al., 2006). Whether HIV-1 spikes cluster
upon encountering a target cell to form an entry claw (Sougrat
et al., 2007) is not relevant to the mechanism of action of our
reagents because neutralization assays are conducted by incu-
bating potential inhibitors with virions prior to addition of target
cells (Montefiori, 2005), a mechanism that is also presumably
relevant for most in vivo interactions of antibody and antibody-
like inhibitors. Because avidity effects require recognition of
two or more antigens tethered to the same surface, another po-
tential action of our reagents, inter-virion crosslinking, would not
result in avidity effects by analogy to the lack of avidity enhance-
ment for an IgG binding two soluble antigens, one per Fab. In this
respect, we note that, although IgAs are capable of inter-virion
crosslinking (Stieh et al., 2014), conversion of IgG bNAbs toCell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc. 441
IgAs did not result in potency increases (Kunert et al., 2004; Wol-
bank et al., 2003).
The use of dsDNA- and protein-based molecular rules to mea-
sure inter-epitope distances presented here can be used to
probe conformations of virion-bound Env trimers. By contrast,
EM and X-ray structures (Bartesaghi et al., 2013; Julien et al.,
2013a; Lyumkis et al., 2013; Pancera et al., 2014) cannot capture
dynamic information concerning Env conformations during
neutralization. Single-molecule fluorescence resonance energy
transfer (smFRET) measurements suggested that Env trimers
on the surface of HIV-1 virions transition between different con-
formations (Munro et al., 2014), and spike trimers have been
visualized by EM in different conformations: the closed structure
of unliganded trimers and trimers associated with VRC01-like
bNAbs (Bartesaghi et al., 2013; Liu et al., 2008; Lyumkis et al.,
2013) (also observed in Fab-bound crystal structures [Julien
et al., 2013a; Pancera et al., 2014]), a CD4- and/or 17b-bound
open structure (Liu et al., 2008; Tran et al., 2012), and a partially
open b12-bound structure (Liu et al., 2008) (Figure 3A). Homo-
and hetero-diFabs joined by different lengths of dsDNA bridges
offer a new methodology to probe Env trimer conformational
states on virions and potentially to address strain-specific
conformational differences.
Homo-diFabs constructed from VRC01-like bNAbs showed
greatest potency when binding to epitopes separated by dis-
tances most closely approximating the open structure (Liu
et al., 2008; Tran et al., 2012), rather than the closed structure
observed for soluble and virion-associated spike trimers bound
to VRC01-like Fabs (Bartesaghi et al., 2013; Liu et al., 2008;
Lyumkis et al., 2013) (Figures 2B, 3, S3, and S4). These results
suggest that optimal intra-spike crosslinking molecules can
inhibit a different state than recognized by monovalent Fabs
binding to spike trimers in static EM and X-ray structures (Barte-
saghi et al., 2013; Liu et al., 2008; Lyumkis et al., 2013; Merk and
Subramaniam, 2013; Tran et al., 2012). If so, one Fab of a homo-
diFab could first bind to its epitope on a closed trimer, allowing
the second Fab to latch on to a transiently populated open
form of that trimer. Alternatively, binding of the first Fab may
trap the trimer into a conformation allowing increased accessi-
bility of the second Fab, or both Fabs could bind simultaneously
to a transiently appearing open trimer. Interestingly, the distance
dependence of two CD4bs antibodies, 3BNC60 and b12, was
more strongly pronounced for a Tier 1B HIV-1 strain, 6535.3,
than for Tier 2 or 3 strains against which the homo-diFabs
were tested (Figures 2B and S2). Tier categorization of HIV-1
strains refers to the sensitivity of a strain to antibody neutraliza-
tion, with Tier 1 strains being more sensitive in general to anti-
bodies than Tier 2 or 3 strains (Seaman et al., 2010). The differ-
ences in length dependence for CD4bs homo-diFabs may
reflect differences in conformational variability within Env trimers
from different tiers, with Tier 1 Env perhaps more easily able to
adopt the open conformations likely recognized by the CD4bs
antibodies with optimal bridge lengths.
For the PG16-3BNC60 hetero-diFabs, the optimal 40 bp and
50 bp bridge lengths (136 A˚ and 170 A˚, respectively) corre-
sponded to the approximate separation distances between
PG16 and 3BNC60 Fabs when bound to the same gp120 within
a trimer (147 A˚) or to neighboring protomers within open or442 Cell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc.partially open trimers (167 A˚) (Figure S3). In a second hetero-
diFab bridge length dependency example, 10-1074-40bp-
3BNC60wasmore potent than 10-1074-60bp-3BNC60 (Figure 4
and Table S4). The136 A˚ distance between the two Fabs in 10-
1074-40bp-3BNC60 corresponded to the approximate separa-
tion between these Fabs bound to the same gp120 (141 A˚),
whereas 60 bpmore closely approximated Fabs bound to neigh-
boring protomers on an open trimer (193 A˚) (Figure S3). In gen-
eral, it is more difficult to deduce information about Env trimer
conformations recognized by hetero-diFabs because the intra-
epitope distance is the same in the three conformations for
Fabs binding to the same gp120 subunit within an Env trimer
(Figure S3), and length-dependence data for some of the het-
ero-diFabs (e.g., 10-1074-40bp-3BNC60) were consistent with
binding to a single gp120 within an Env trimer, as well as to adja-
cent gp120s (Figure S2). However, whether binding to the same
or to adjacent protomers within the spike trimer, the increased
synergy of optimal hetero-diFabs suggested a mechanism in
which the more potent/tighter-binding Fab of the hetero-diFab
initially bound to the viral spike, thereby allowing the second
Fab, even when only weakly neutralizing on its own, to attach.
In summary, our results demonstrated that optimal length
homo- and hetero-diFabs are capable of synergistic effects
that increased neutralization potencies and, in some cases, al-
lowed neutralization of viral strains resistant to conventional
IgGs. These results are consistent with the hypothesis that
most anti-HIV-1 IgGs bind monovalently to single Env spikes,
which leaves them vulnerable to Env mutations that weaken
monovalent interactions but would still permit bivalent interac-
tions (Klein and Bjorkman, 2010). The demonstration that anti-
HIV-1 reagents designed to be capable of intra-spike binding
with avidity can more potently and broadly neutralize HIV-1
than conventional anti-spike IgGs is relevant to the choice of
anti-HIV-1 proteins or genes to be delivered passively to prevent
infection or suppress active infections. Bi-specific antibodies
that simultaneously bind to HIV-1 Env and to CD4 or CCR5
host receptors on the target cell represent a conceptually distinct
method to increase the potency and breadth of anti-HIV-1 re-
agents (Pace et al., 2013). In contrast to these reagents, anti-
bodies that achieve synergy via bivalent binding to Env by
intra-spike crosslinking offer significant advantages for passive
delivery; for example, neutralizing antibodies against HIV-1 Env
protect more effectively in vivo than antibodies against CD4
(Pegu et al., 2014), and anti-self antibodies such as anti-CD4
IgGs have short half-lives in vivo (Bruno and Jacobson, 2010).
We propose that the ideal therapeutic molecule would utilize
avidity achieved by intra-spike crosslinking to reduce the con-
centration required for sterilizing immunity and render the low
spike density of HIV-1 irrelevant to its efficacy. Moreover, analo-
gous to using several drugs or antibodies during anti-retroviral
therapy, simultaneous binding to different HIV-1 epitopes should
reduce or abrogate sensitivity to Env mutations.EXPERIMENTAL PROCEDURES
Expression and Purification of Fabs
Genes encoding IgG light-chain genes were modified by site-directed muta-
genesis to replace Cys263Light Chain, the C-terminal cysteine that forms a
disulfide bond with Cys233Heavy Chain, with a serine. Modified light-chain genes
and genes encoding 6x-His- or StrepII-tagged Fab heavy chains (VH-CH1-tag)
were subcloned separately into the pTT5 mammalian expression vector (NRC
Biotechnology Research Institute). Fabswere expressed by transient transfec-
tion in HEK293-6E (NRC Biotechnology Research Institute) cells as described
(Diskin et al., 2011) and purified from supernatants by Ni-NTA or StrepII affinity
chromatography followed by size exclusion chromatography in PBS pH 7.4
using a Superdex 200 10/300 or Superdex 200 16/600 column (Amersham
Biosciences).
IgG heterodimers were expressed and purified as described in the Extended
Experimental Procedures.
DNA Conjugation to Fabs
DNAwas conjugated to free thiol-containing Fabs using amodified version of a
previously described protocol (Hendrickson et al., 1995). Briefly, Fabs were
reduced in a buffer containing 10 mM TCEP-HCl (pH 7–8) for 2 hr and then
buffer exchanged three times over Zeba desalting columns (Thermo Scienti-
fic). The percentage of reduced Fab was determined using Invitrogen’s Mea-
sure-IT Thiol Assay. Concurrently, a 5–20 base ssDNA containing a 50 amino
group (Integrated DNA Technologies, IDT-DNA) was incubated with a 100-
fold molar excess of an amine-to-sulfhydryl crosslinker (Sulfo-SMCC; Thermo
Scientific) for 30 min to form a maleimide-activated DNA strand, which was
buffer exchanged as described above. The reduced Fab and activated ssDNA
were incubated overnight, and the Fab-ssDNA conjugate was purified by Ni-
NTA or StrepII affinity chromatography (GE Biosciences) to remove unreacted
Fab and ssDNA.
ssDNA was synthesized, phosphorylated, and PAGE purified by Integrated
DNA Technologies. For di-Fabs containing dsDNA bridges longer than 40 bp,
complementary ssDNAs were annealed by heating (95C) and cooling (room
temperature) to create dsDNA containing overhangs complementary to the
Fab-ssDNA conjugates. dsDNA was purified by size exclusion chromatog-
raphy (Superdex 200 10/300) and incubated overnight with the correspond-
ing tagged Fab-ssDNA conjugates. Homo- and hetero-diFab reagents were
purified by Ni-NTA and StrepII affinity chromatography when appropriate to
remove free DNA and excess Fab-ssDNA conjugates, treated with T4 DNA
ligase (New England Biolabs), and purified again by size exclusion chroma-
tography (Figure S1B). To make di-Fabs containing dsDNA bridge lengths
less than 40 bp, two complementary ssDNA-conjugated Fabs were incu-
bated at 37C without a dsDNA bridge and then purified as described above.
Protein-DNA reagents were stable at 4C for >6 months as assessed by
SDS-PAGE.
Bridge and linker sequences are listed in Extended Experimental
Procedures.
Characterization of DNA-Fab Reagents
Fractions from the center of an SEC elution peak were concentrated using
Amicon Ultra-15 Centrifugal Filter Units (Millipore) (MW cutoff = 10 kDa) to a
volume of 500 ml, and DLS measurements were performed on a DynaPro
NanoStar (Wyatt Technology) using the manufacturer’s suggested settings.
Hydrodynamic radii were determined as described (Dev and Surolia, 2006).
Briefly, a nonlinear least-squares fitting algorithmwas used to fit the measured
correlation function to obtain a decay rate. The decay rate was converted to
the diffusion constant that can be interpreted as the hydrodynamic radius
via the Stokes-Einstein equation.
Hetero-diFab with TPR Linker
PG16-TPR12-3BNC60, a C-to-C linked hetero-diFab containing 12 consensus
TPR domains (Kajander et al., 2007) as a protein linker (Klein et al., 2014), was
prepared from modified PG16 and 3BNC60 Fabs using a combination of sor-
tase-catalyzed peptide ligation and click chemistry (Witte et al., 2013). The C
terminus of the PG16 Fab heavy chain was modified to include the amino
acid sequence GGGGASLPETGGLNDIFEAQKIEWHEHHHHHH, comprising
a flexible linker, the recognition sequence for S. aureus Sortase A (underlined),
a BirA tag, and a 6x-His tag. The C terminus of the 3BNC60 Fab heavy-chain C
terminus was modified to include a (Gly4Ser)3 linker followed by 12 tandem
TPR domains and the amino acid sequence ASGGGGSGGGGSGGGGS
LPETGGHHHHHH, comprising a second (Gly4Ser)3 linker, the Sortase Arecognition sequence (underlined), and a 6x-His tag. The Fabswere expressed
in HEK-6E cells and purified with Ni-NTA and gel filtration chromatography as
described above. Peptides (GGGK with C-terminal azide and cyclooctyne
click handles) were synthesized by GenScript, and sortase-catalyzed peptide
ligation was used to attach the azide-containing peptide to PG16 Fab and the
cyclooctyne-containing peptide to the 3BNC60-TPR12 fusion protein as
described (Guimaraes et al., 2013). Approximate yields after each sortase re-
action were 30%. Peptide-ligated PG16 and 3BNC60 Fabs were passed
over a Ni-NTA column to remove His-tagged enzyme and Fabs that did not
lose their His tags during the reaction, mixed at equimolar ratios, and the click
reaction was accomplished by incubating overnight at 25C. The approximate
yield for the click reaction was 65%. The resulting PG16-TPR12-3BNC60
hetero-diFab was purified by size exclusion chromatography to remove un-
reacted Fabs for an overall yield of 22%.
Measurements of Intra-Spike Distances
To derive predicted distances between two adjacent Fab bound to HIV-1 Env,
we superimposed Fabs bound to their epitopes on the structures of Env tri-
mers in three different conformations: closed (a 4.7 A˚ crystal structure of a
gp140 SOSIP trimer; PDB code 4NCO), open (a 9 A˚ EM structure of a SOSIP
trimer-17b Fab complex (Tran et al., 2012); coordinates obtained from S. Sub-
ramaniam), and partially open (an20 A˚ EM structure of a viral spike bound to
b12 Fab; PDB code 3DNL). The positions of the CH1 and CL domains in Fab
structures used for docking were adjusted to create Fabs with the average
elbow bend angle found in a survey of human Fab structures (Stanfield
et al., 2006). The VH-VL domains of the adjusted Fabs were then superimposed
on crystal structures of Fab-gp120 or Fab-gp140 complexes (PDB codes
3NGB, 2NY7, and 4CNO for complexes with VRC01, b12, and PGT122
Fabs, respectively) or a PG16-epitope scaffold complex (PDB code 4DQO).
The position on Env trimer of 10-1074, a clonal variant of the PGT121-
PGT123 family (Mouquet et al., 2012), was approximated using the 4CNO
gp140–PGT122 structure. In other cases, related antibodies, e.g., PG9/
PG16 and VRC01/3BNC117/3BNC60, were also assumed to bind similarly.
The complex structures were superimposed on the Env trimer structures
by aligning the common portions. The distance between the Cys233heavy chain
carbon-a atoms of adjacent Fabs was then measured using PyMol (Schro¨-
dinger, 2011) to approximate the length of dsDNA bridges attached to
Cys233
heavy chain
. Measurements derived using other EM structures for the closed
and open trimers (PDB codes 3DNN, 3J5M, and 3DNO) or using a recent 3.5 A˚
Env trimer crystal structure (Pancera et al., 2014) resulted in differences of%
10 A˚ for analogous distance measurements.
In Vitro Neutralization Assays
Neutralization of pseudoviruses derived from primary HIV-1 isolates wasmoni-
tored by the reduction of HIV-1 Tat-induced luciferase reporter gene expres-
sion in the presence of a single round of pseudovirus infection in TZM-bl cells
as described previously (Montefiori, 2005) and in the Extended Experimental
Procedures.
Simulation of Fab and IgG Saturation of Surface-Bound Antigens
Numerical analysis (Mathematica, v. 10) was used to simulate saturation of
surface-bound antigens by monovalent Fabs (Equation 1), bivalent IgGs to un-
paired antigen (Ag) (Equation 2), and paired antigen (pAg) (Equations 3 and 4),
where ‘‘paired antigen’’ was defined as antigens that are spaced such that an
IgG can bind two epitopes simultaneously (e.g., intra-spike crosslinking of two
epitopes on the same viral spike or inter-spike crosslinking between two viral
spikes). In the bivalent model (Equations 3 and 4), the surface concentrations
of antigen and IgG-antigen complexes were approximated by the inverse of
the volume of a sphere (Vs) with radius equal to the hydrodynamic radius of
the molecule multiplied by Avogadro’s number (Na) as described previously
(Mu¨ller et al., 1998).
Fab binding to antigen:
Fab+Ag%Fab  Ag
d½Fab Ag
dt
= ka½Fab½Ag  kd ½Fab  Ag (Equation 1)Cell 160, 433–446, January 29, 2015 ª2015 Elsevier Inc. 443
IgG binding to unpaired antigen:
IgG+Ag%IgG Ag
d½IgG Ag
dt
= 2ka½IgG½Ag  kd½IgG Ag (Equation 2)
IgG binding to paired antigen:
IgG+pAg%IgG pAg
IgG pAg+pAg%IgG pAg2
d½IgG pAg
dt
= 2ka½IgG½pAg  kd ½IgG pAg  d½IgG pAg2
dt
(Equation 3)
d½IgG pAg2
dt
= ka½IgG pAg 1
Vs Na
½pAg 1
Vs Na
 2kd ½IgG pAg2
(Equation 4)
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